This is an aggregated industry headline. Read the full story at FierceBiotech →
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
Novo's attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two years.
By FierceBiotech
· Sep 15, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekBriefing
The government released 2027 Medicare Advantage quality ratings, and early coverage singled out Humana as the …
The WeekPharmaceutical Technology ↗
Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist ra…
The WeekAJMC ↗
Using Complement Inhibitors in GA Comes With Pros and Cons…